



innovotech

EXPERTS in antimicrobial contract research and biofilm solutions.

TSXV: IOT

Corporate Presentation Q3-2024

EXECUTIVE SUMMARY



Innovotech is a Canadian microcap biotech company with deep client relationships, 20+ years of technical expertise, proprietary methods and intellectual property.

Our strategy is to build a diverse portfolio of revenue generating business lines while supporting targeted research for high value intellectual properties.


Traded Since 2004 on the TSXV: IOT
Current Price C\$0.13

52 week high C\$0.15

Market Cap C\$5.08mm

39mm Shares outstanding

Team of 15 Industry Professionals



INNOVOTECH LEADS by creating technologies, products, and services aimed at improving health by reducing the burden of infection.



WHAT SETS US APART



The **developer of the standard method** ASTM E2799 for biofilm investigations

MBEC Assay® kits are a proprietary high-throughput screening assays used to determine the efficacy of antimicrobials against biofilms of a wide variety of microorganisms.



A **trusted testing and supporting partner** on 510(k), FDA and other regulatory submissions

BEST Assay™ testing devices and methods have been used in successful FDA 510(k) submissions for coated medical devices.



Effective Quality System with **ISO 17025:2017** accredited

Accredited by CALA to ISO/IEC17025 Testing Accreditation No. A4146 for enumerating bacteria – liquids and solids.



Traded on the **TSX-Venture Exchange**

TSX-V:IOT has been publicly-traded since 2004.



Patented IP, proven methodologies and decades of know how

A well-known industry leader. We can leverage our market positioning, deep expertise, client relationships and IP to grow a diverse biotech company.

THE EXECUTIVE TEAM



CRAIG MILNE
MBA, Ph.D.
CEO, DIRECTOR

Entrepreneurial leader with proven track record of growing technology-enabled companies.



PATRICIA NADWORN
Ph.D., P.Eng.
CSO

Chemical & biomedical engineering leader with domain expertise in antimicrobial silver compounds, biofilms and medical devices.



TYLER BOONE
Ph.D.
COO

Operations leader with PhD in microbiology. Leads client relations and contract research services.



BERNARD GROBBELAAR CPA
CFO

CPA/CA with more than two decades of experience serving clients in the public, private, and not-for-profit sectors.

BOARD OF DIRECTORS



JAMES TIMOURIAN
Board Chair

Entrepreneur, Investor, former mathematics professor



CRAIG MILNE

Entrepreneurial leader with proven track record of growing technology-enabled companies



JULIE WRIGHT

Investor, marketing and public relations agency owner. California-based.



DAVID TAM

Corporate Lawyer with decades of experience in capital markets




KAREN FARKAS

Entrepreneur, former accounting professor

A PRIMER ON MICROBIAL BIOFILMS

FREE-FLOATING MICROBES ARE PLANKTONIC

- The focus of 200 years of research and understanding
- Basis for regulatory standards, and development of disinfectants, antibiotics and other treatments
- 20% of the commercial and health impacts



COMMUNITIES OF MICROBES ARE BIOFILMS

- Little knowledge, little awareness
- Few products and difficult to study
- Different biology than planktonic – significant antimicrobial resistance
- 80% of the commercial and health impacts
- Economic significance in excess of \$5T
[<https://www.nature.com/articles/s41522-022-00306-y>]

Selected Market Opportunities

1 HOSPITAL ACQUIRED INFECTIONS

- In Canada, >220,000 hospital acquired infections (HAIs) annually
- Costs system ~\$1B CAD
- 8,000 deaths annually
- In US, ~1.7M HAIs/year
- Costs system ~\$28.4B USD
- 99,000 deaths annually

2 CATHETER ASSOCIATED INFECTION

- Catheter associated bloodstream infection affects 5% of hospitalized adults with peripherally inserted central catheter.
- Failure costs USD\$11-\$69k/episode
- Single use urinary catheters create a 5% risk per day of patient developing urinary tract infection.
- \$1k problem and if hospitalization required \$7.7k

3 CHRONIC WOUNDS

- 2% of the US population has a chronic wound
- Costs >\$50B USD/y
- More than 1.6% of patients die
- Cost to care for diabetic foot ulcers alone in Canada is \$509M CAD/y


Total market size for antimicrobial wound dressings anticipated to have reached **~\$1.4B USD in 2023**

Global antimicrobial coatings market estimated to reach **~\$7.6B USD in 2025**

INNOVOTECH Operates in four business sectors




MBEC ASSAY[®] KITS



- Renewed effort in sales
- Expanded product line
- Simplification of methods for greater access
- Improved efficiency of production and support




CONTRACT RESEARCH



- Renewed effort in sales
- New service offerings
- Greater exposure of our work and impact



INNOVOSIL[™]-1 SILVER



- Partnerships for commercialization
- Continued R&D
- Publications and patents to support findings





NEW TECHNOLOGIES



- Partnerships for commercialization (NouLife)
- Continued search for M&A opportunities or development of new business units



MBEC ASSAY® KITS




Consumable Lab Supplies Required for Standard Antibiofilm Tests

- Typical purchasers are **industrial researchers, academia** and **governments**
- Basis for ASTM E2799 Method
- **Worldwide sales** direct from our webstore www.innovotech.ca
- Innovotech retains **proprietary manufacturing methods**
- **MBEC Assay® Kits** come in different coatings for different use cases
- **15-20% OF SALES**



**CONTRACT
RESEARCH**




Leading Contract Research Organization for Antimicrobial Surface Testing

- **Major global** medical device companies as clients
- **Certified by CALA** to ISO 17025.
- Testing has been **successfully used for FDA 510(k) submissions**
- Innovotech provides **research support** and **third-party testing**, as companies develop new coatings or products and plan to seek FDA-clearance for antimicrobial surface claims.
- Typically 80-85% of revenues



INNOVOSIL™-1 SILVER



Patented Antimicrobial Silver Family of Compounds

- New class of silver-iodine complexes
- Silver protected by high oxidation state iodine
- Iodine facilitates silver transfer through biofilm

InnovoSIL™-1 silver

- Broad spectrum activity: shown to be effective against mature biofilms, super bugs and respiratory viruses including COVID-19
- Slow-release properties allow for continuous release to prevent adherence from surfaces and eliminate surrounding microbes
- Multiple mechanisms of action; less likelihood of developing resistance
- Small grain size + polycrystallinity + surface area for improved antimicrobial activity



NEW TECHNOLOGIES



NouLife Sciences Inc.

- 2023: Purchased IP-holding company with **patented technology** for advanced penetration of linked **antioxidant molecules** for diabetic neuropathy and cosmetic applications
- **Successfully synthesized** linked molecule with 3 linkers
- Completed **stability studies**
- Ongoing **permeability studies**
- Seeking commercialization **partnerships**

CAUTIONARY NOTE

Regarding Forward-Thinking Statements

This document may contain forward-looking statements that are predictive in nature and subject to risks and uncertainties that cannot be predicted or quantified; consequently, actual results may differ materially from past results and those expressed or implied by any forward-looking statements.

Factors that could cause or contribute to such risks or uncertainties include, but are not limited to: the regulatory environment including the difficulty of predicting regulatory outcomes; changes in the value of the Canadian dollar; the Company's reliance on a small number of customers; fluctuations in operating results; government policies or actions; reliance on key strategic relationships; uncertainty related to intellectual property protection and potential costs associated with its defence; the Company's exposure to lawsuits and other matters beyond the control of management.

Should known or unknown risks or uncertainties materialize, or should management's assumptions prove inaccurate, actual results could vary materially from those anticipated. The Company undertakes no obligation to publicly make or update any forward-looking statements, except as required by applicable law.



innovotech

CRAIG MILNE, CEO

+1-604-239-1819

craig.milne@innovotech.ca

Innovotech.ca